ABSTRACT
Purpose:
To evaluate whether any topical anti-glaucoma medications increase the risk of lacrimal drainage system obstruction or whether the presence of preservatives alone is sufficient to generate obstruction.
Methods:
This nested case-control study compared a group of patients with lacrimal duct obstruction who received topical anti-glaucoma medications to a control group of patients without obstruction.
Results:
The medical records of 255 patients with glaucoma who consulted the Oculoplastic Section with complaints of watery eyes were reviewed. Among these patients, 59 exhibited lacrimal drainage obstruction. Ninety-four percent of patients with lacrimal drainage obstruction used beta-blockers, and 41% used prostaglandin analogs. A logistic regression model was used to adjust for age, sex, and the use of other medications. No significant differences were observed regarding the topical anti-glaucoma medications used between groups.
Conclusion:
No single topical anti-glaucoma medication demonstrated a stronger association with the development of lacrimal duct obstruction.
Keywords:
Lacrimal duct obstruction; Glaucoma; Preservatives pharmaceutical; Lacrimal apparatus diseases; Ophthalmic solutions